Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Lonza and Agennix Sign Development and Manufacturing Deal for Production of Talactoferrin

Published: Thursday, April 19, 2012
Last Updated: Thursday, April 19, 2012
Bookmark and Share
Lonza will manufacture talactoferrin at its microbial facility in Kourim, Czech Republic.

Lonza and Agennix AG have announced an agreement for the production of Agennix’s first-in-class oral Dendritic Cell Mediated Immunotherapy (DCMI), talactoferrin, currently in Phase III testing for the treatment of non-small cell lung cancer (NSCLC).

Under the agreement, Lonza will produce commercial material at its microbial manufacturing facility in Kouřim, Czech Republic.

This agreement initiates the process needed to be able to ultimately seek approval for Lonza as a second manufacturer of talactoferrin after the initial commercial launch.

“We are committed to supporting emerging therapeutics through clinical trial milestones,” said Dr. Stephan Kutzer, COO Lonza Custom Manufacturing.

Dr. Kutzer continued, “Our partnership with Agennix is an example of this commitment and demonstrates Lonza’s ability to offer access to our development and manufacturing expertise at an early stage of production.”

Rajesh Malik, M.D., Chief Medical Officer and Management Board member of Agennix, said: “We are pleased to enter this agreement with Lonza, which has extensive experience manufacturing biologics on a commercial scale. In anticipation of positive Phase III data and a potential product approval, it is important that we have more than one manufacturer in place to ensure we can meet anticipated commercial demand and that we have security of supply.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Lonza to Continue Sponsoring Horseshoe Crab Conservation Initiatives Through 2016
Lonza to continue sponsorship of horseshoe crab conservation initiatives by the Ecological Research & Development Group (ERDG).
Wednesday, June 15, 2016
Leading Industry Experts to Present at Lonza’s 2nd Global Endotoxin Testing Summit
A growing list of industry experts have signed up to join the speaker panel at Lonza’s 2nd Global Endotoxin Testing Summit from 23-25 May 2016, Annapolis, MD, and Pickering Beach, DE (USA).
Tuesday, March 01, 2016
Lonza to Build Capabilities for Drug Product Development
Company to Develop Drug Product Services for Customers by building its capabilities step-wise over the coming years.
Friday, February 05, 2016
Lonza to Build Capabilities for Drug Product Development Services
Lonza is entering the field of Drug Product Development Services for customers by building its capabilities step-wise over the coming years.
Friday, February 05, 2016
Lonza and Benitec Enter Agreement
Agreement to develop scalable AAV manufacturing process for ddRNAi therapeutics.
Friday, October 09, 2015
Lonza and CytoMate Collaboration on CytoSMART™ Technology
Agreement for global distribution of the new technology which is designed for easy, affordable live cell imaging.
Thursday, March 05, 2015
Lonza and arGEN-X Announces Commercial License Agreement
A multi-product GS Xceed™ license agreement for the production of therapeutic antibodies.
Friday, February 20, 2015
Lonza and BioWa Sign Licensing Agreement with MedImmune
MedImmune has licensed Potelligent® CHOK1SV Cell Line Technology to both Companies.
Monday, December 16, 2013
Lonza and Hyglos Reach Agreement for Endotoxin Detection Patents
Agreement allows Hyglos to use recombinant factor C technology to produce its own endotoxin products.
Friday, March 15, 2013
Lonza to Expand ADC Manufacturing Capacity
Capacity expansion is expected to be complete in the second quarter of 2014.
Thursday, January 10, 2013
Lonza Appoints Richard Ridinger as New CEO
Board of Directors elects Mr. Ridinger at a meeting on 2 April 2012.
Thursday, April 05, 2012
Lonza Expands Singapore Bioservices
The expansion will support cell line construction, upstream and downstream process development, and a broad range of analytical services.
Monday, June 13, 2011
Lonza Selects IDBS to Optimize Bioprocess Execution & Knowledge Management
Lonza has chosen IDBS to provide an electronic data management and execution solution for mammalian cell culture process development. Lonza will deploy IDBS's Bioprocess Execution System to optimize the management of process development data and drive operational excellence.
Wednesday, January 05, 2011
Lonza Acquires Viral Vaccine and Vector Manufacturer Vivante GMP Solutions
Lonza expands its custom service platform to viral vaccines and gene therapy vectors.
Tuesday, August 31, 2010
Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement
Lonza provides process development services and manufacturing capacity for this product using Lonza's GS Gene Expression System™.
Wednesday, June 17, 2009
Scientific News
Open Source Seed Initiative – A Welcome Boost to Global Crop Breeding
A team of plant breeders, farmers, non-profit agencies, seed advocates, and policymakers have created the Open Source Seed Initiative.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Anthrax Proteins Might Help Treat Cancerous Tumors
Studies in mice reveal novel treatment regimen.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Key to Chronic Fatigue Syndrome is in Your Gut, Not Head
Researchers report they have identified biological markers of the disease in gut bacteria and inflammatory microbial agents in the blood.
HIV Structure Stabilized
Findings represent ‘big accomplishment’ in biomedical engineering and design.
Four Newly-Identified Genes Could Improve Rice
A Japanese research team have applied a method used in human genetic analysis to rice and rapidly discovered four new genes that are potentially significant for agriculture. These findings could influence crop breeding and help combat food shortages caused by a growing population.
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Antibodies To Dengue May Alter Course Of Zika Virus Infection
Scientists at Emory Vaccine Center, in collaboration with investigators from Thailand, have found that people infected with dengue virus develop antibodies that cross-react with Zika virus.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!